All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for AMGEN · Biotechnology.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 6

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 3

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 4

Medicare/Medicaid

Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management. Monitored issues related to dialysis services. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to pharmacy benefit management and drug pricing policies. H.R. 946 / S. 1862, ORPHAN Cures Act. Issues related to the Most Favored Nation drug pricing.

Health Issues

Issues related to pharmacy benefit management. Issues related to cardiovascular care. Issues related to drug pricing.

Monitored issues related to intellectual property.

Taxation/Internal Revenue Code

H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.